[
    "**Euthanasia and laparotomy**",
    "1| Euthanize mice \\(inject i.p. 12.5 \u00b5g Avertin in 100 \u00b5l NaCl per 10 g body weight or use 1.5-2% isoflurane inhalation, TEM Sega, France), shave with electric trimmer, disinfect in 70% \\(vol/vol) ethanol for 1 min then immobilize at the back-down position on the dissection pad \\(Styrofoam or equivalent support) by the fore,- and hind -limbs using elastic rings.",
    "Place the platform under a viewer light source. ",
    "\u25cfTIMING After a single Avertin injection mice become immobile within 2-3 min, remain anesthetized for 15-20 min and will recover within 30-60 min. ",
    "\\!CAUTION Animal experiments are to be performed in accordance with institutional and national guidelines.",
    "Respect death criteria rigorously prior to any surgical interventions \\(immobility, eyeball blinking, heart beating, breathing and inertia to pain).  ",
    "2| Cut the skin first from the pubis along the sternum and then the wall of abdomen using scissors and forceps, then fix the skin aside by pins.",
    "Pull the liver carefully, cut the diaphragm and then cut the ribs along the chondro-osseuse joints bilaterally; turn-up and immobilize the sternum by a needle \\(G 22) to uncover the heart.",
    "Rinse the thorax and abdomen with Ca<sup>2+</sup>, Mg<sup>2+</sup>-free PBS supplemented with 10 mM EDTA.",
    "Lift the liver and digestive tube and dislodge on the left side gently to facilitate trans cardiac perfusion.",
    "?",
    "TROUBLESHOOTING Keep main blood vessels intact and avoid visceral tissues to compress. ",
    "**Whole-body perfusion**",
    "3| Hold the heart with lightweight tweezers and introduce the butterfly cannula \\(BD Venflon, 0.8x32 mm) via the heart apex and left ventricle into the ascending aorta.",
    "Hole the right atrium and perfuse mice with 20-30 ml pre-warmed 0.9% \\(wt/vol)",
    "NaCl \\(37 C\u00b0, 110 cm height/pressure). ",
    "\u25cf TIMING 10 min ",
    "\u25a0 PAUSE POINT Continue either with Fig. 1 C| micro-dissection, Fig. 1 D|  BM fractionation \\(Supplementary Video 1a-d), Fig.",
    "1 E|, F|, G| and H| quantitative determinations, Fig.1 I| laser scanning confocal microscopy,  Fig.1 J| transmission electron microscopy or Fig.1 K| \u00b5CT imaging.",
    "**Microdissection and fractionation of mouse femoral BM** ",
    "Supplementary Video 1a-d|: Microdissection of femur under the stereomicroscope",
    "4| Strip the hind limbs, dissect femurs aseptically and cut muscle and tendon under 4 ml PBS containing 0.5% \\(wt/vol)",
    "BSA containing double strength antibiotic-antimycotic solution at +4 \u00b0C in a 60 mm Petri dish.",
    "Detach and remove the distal epiphysis.",
    "Rinse, then transfer cleaned femurs in a 35 mm Petri dish containing 4 ml IMDM containing 4% \\(vol/vol) FCS. ",
    "\u25a0 PAUSE POINT Cleaned femurs in IMDM/4% FCS can be pooled on ice for a few h.",
    "\u25cf TIMING Preparation of two femurs takes 20 min",
    ".",
    "5| Place the dish under the dissection microscope.",
    "Hold the femur firmly with serrated forceps, section the distal spongiosa in halves and then bisect the compact diaphysis bone longitudinally making tiny, continuous holes using a sharp scalpel \\(#15A) along one side and then along the opposite side of femur.",
    "Open the two halves to uncover the BM shaft. ",
    "\u25b2CRITICAL STEP To recover the whole, intact marrow parenchyma, apply the fine scalpel carefully to make tiny holes only in the bone along the femur.",
    "Change medium to remove joint, bone spikes or muscle fragments prior to BM fractionation.  ",
    "?",
    "TROUBLESHOOTING Hardness of the cortical bone varies with age and is different in low or high bone-density mouse strains.",
    "The instruments should be adapted accordingly, for example, use watchmaker forceps and 25 G needle to bisect femurs in perinatal and young mice.  ",
    "6| BM attaches to the endosteal bone surface by different forces depending on the anatomical locations, i.e. loosely at the cylindrical diaphysis and firmly at the spongy metaphysis \\(Fig.2| and Fig.3|).",
    "Following longitudinal bisection of femur aspirate the BM shaft from the central diaphysis using a 200-\u00b5l pipette tip and transfer this in a polystyrene tube filled with 2 ml IMDM supplemented with 2% \\(vol/vol) FCS \\(Tube-B).",
    "Dilacerate the metaphyseal spongiosa by fine scalpels to open the spongy meshwork, remove the loosely attached suspension and haematon nodules by harmless trituration and then pool this fraction in Tube-B. Scrape out the whole, inner endosteal/spongy bone cushion and transfer this pellet into Tube-C. ",
    "Separate the whole, pooled BM parenchyma \\(Tube-B) into two fractions, i.e. the buffy coat suspension and haematon nodules.",
    "Dissociate and erode the whole BM by three up-and-down aspirations via a 23 G needle and then allow nodules to settle during 10 min on ice.",
    "Transfer the supernatant suspensions in a 15-ml tube \\(Tube A).",
    "Add 1 ml fresh medium to the pellet and repeat the dispersion/erosion step two times using 25 G needles.",
    "Pool the supernatant suspensions to constitute the buffy coat fraction and conserve the nodular pellet containing haematons. ",
    "The procedure results in three defined fractions:",
    "Tube A - Fraction 1: buffy coat single-cell suspension; Tube B - Fraction 2: nodular haematon units and Tube C \u2013 Fraction 3:  endosteum/spongy bone \\(EOSB) containing firmly attached BM, mainly haematons, ",
    " <a href=\"#figures\" data-url=\"http://path.to/image.ext\">See figure in Figures section.</a>\\(Fig.",
    "2|<a href=\"#figures\" data-url=\"http://www.nature.com/protocolexchange/system/uploads/2401/thumbnail/Figure_2.png?1357726384\">See figure in Figures section.</a>)",
    "<a href=\"#figures\" data-url=\"http://path.to/image.ext\">See figure in Figures section.</a>",
    "**Enumeration of haematon units**",
    "7|",
    "Native haematon isolates.",
    "Stir up the purified haematon pellet in 1 ml standard culture medium \\(Zn-7 fixative can be used instead).",
    "Transfer 50 \u00b5l aliquot on a cleaned glass slide, remove occasional bone spikes and bubbles under the stereomicroscope and then cover the preparation with a 60x25 mm cover slip.",
    "Count compact aggregates under the microscope at low magnification \\(Fig.",
    "2B|). ",
    "\u25cfTIMING 15 min ",
    "\u25b2CRITICAL STEP Native haematons may occur in larger co-aggregates \\(see for example Fig.3Ba| and Fig.3Bb|).",
    "Continue mild dispersion through a 25G needle, or use digital image erosion36 to recognize and count individual haematon units. ",
    "8|",
    "Haematon counting in short-term and long-term organotypic culture \\(Hem-LOC).",
    "Plate aliquots in Hydron bordered 25-sq cm flask filled with 4 ml My-LTCM and incubate the cultures in a CO<sub>2</sub> incubator at 33 \u00b0C.",
    "Count haematons at d4 appearing either as rolling/slightly adherent spheroids or fully adherent cobblestone area forming islands \\(CAFI) under the phase-contrast inverted microscope. ",
    "\u25cfTIMING Counting discrete CAFIs in a 25-sq cm flask takes \u02c25 min.",
    "Continue the culture and apply weekly half depopulation and replacement of medium by fresh My-LTCM.",
    "Count CAFIs again at d35 \\(Fig.",
    "2B| and Fig.",
    "4Ab).  ",
    "\u25b2CRITICAL STEP Under the above conditions \u226590% of haematons become adherent and flattened but keep their structural integrity and maintain cell production for several weeks. ",
    "?",
    "TROUBLESHOOTING The absence of structural integrity indicates for inadequate culture medium or culture conditions. ",
    " ",
    "9|",
    "Extrapolate the data from 7| and 8| for the whole femur \\(or other skeleton segment), represent graphically and calculate correlation \\(Fig.",
    "2B|). ",
    "**Functional analysis of haematons ex-vivo using video-microscopy, FACS, clonal bioassays and IH/LSCM**",
    " <a href=\"#figures\" data-url=\"http://path.to/image.ext\">See figure in Figures section.</a>\\(Fig 3|<a href=\"#figures\" data-url=\"http://www.nature.com/protocolexchange/system/uploads/2402/thumbnail/Figure_3.png?1357726386\">See figure in Figures section.</a>)",
    "<a href=\"#figures\" data-url=\"http://path.to/image.ext\">See figure in Figures",
    "section.</a> ",
    "10| Purified haematons maintain their functional activities and produce haematopoietic cells for several weeks in vitro allowing the persistence of HSCs to investigate.",
    "We have shown the application of haematon cultures in three domains.    ",
    "\\(i) Comparative investigation of HSCs with myelo-lymphopoietic potentials<sup>38</sup>  \\(Box 1|).",
    "We have adapted this protocol and shown previously that haematon units can be identified, purified and analysed also from other blood-forming tissues.  ",
    "\\(ii)Foetal mouse liver <sup>SAR-2-3,-6</sup> :\\(Fig.4Ac| and Fig.4Ad| and Supplementary Video 5|).",
    "\\(iii)Adult human BM <sup>SAR-5,-6,-8</sup> :",
    "\\(Fig.4Ae| and Fig.4Af| and Supplementary Video 6|).",
    "Dissociation of BM fractions for single-cell \\(clonal) analyses ",
    "11|",
    "Spin down the BC, haematon and endosteum fractions for 7 min at 400g and discard the supernatants.",
    "12| Add 200 \u00b5l enzyme cocktail \\(0.1% wt/vol collagenase type-I,-II,-IV and 10 I.U. DNase-I) for one femur equivalent pellet at 37\u00b0C for 30 min; triturate cells by a 200-\u00b5l silicon coated pipette tip at 5-10 min intervals.",
    "Stop digestion by 2 ml ice-cold IMDM containing 2% \\(vol/vol) FCS, let resistant aggregates to settle down for 5 min and transfer the supernatants in new 4-ml tubes \\(labelled respectively Pool -A, B and C as above) at +4\u00b0C. ",
    "13| Add 200 \u00b5l collagenase-dispase-hyaluronidase solution to the residual aggregates for an additional 8 min at 37\u00b0C.",
    "Transfer the suspension to POOL tubes and dilute with 4 ml IMDM containing 2% \\(vol/vol) FCS on ice.",
    "Centrifuge \\(400 g, 7 min, +4\u00b0C), wash the pellets twice in IMDM containing 2% \\(vol/vol) FCS and then filter through a 30-\u00b5m mesh nylon filter.",
    "?",
    "TROUBLESHOOTING Verify cryptic haematopoietic cells in the residual bone pellet.",
    "Add 1 ml Ca-free PBS containing 5 mM EDTA twice, for 5 min each.",
    "Force the bony pellet repeatedly using the soft piston from a 1-ml Terumo syringe in order to recover firmly attached cells from the bone surface.  ",
    "\u25b2CRITICAL STEP Working with new enzyme batches, verify the kinetics of tissue dispersion by microscopic analysis of resident tiny aggregates and expression level of Sca-1 and c-kit antigens using FACS \\(Supplementary Fig.1|). ",
    "\u25a0 PAUSE POINT BM fractions can be stored overnight in IMDM supplemented with 4% \\(vol/vol) FCS at +4 \u00b0C for subsequent analysis.   ",
    "**FACS analysis and HSC sorting** ",
    " <a href=\"#figures\" data-url=\"http://path.to/image.ext\">See figure in Figures section.</a>\\(Fig 4|<a href=\"#figures\" data-url=\"http://www.nature.com/protocolexchange/system/uploads/2403/thumbnail/Figure_4.png?1357726387\">See figure in Figures section.</a> )",
    "<a href=\"#figures\" data-url=\"http://path.to/image.ext\">See figure in Figures section.</a> ",
    "14| Count nucleated cells in a haemocytometer using RBC lysis solution and then adjust cell concentration to 0.5-1x10<sup>6</sup> cells per ml PBS containing 4% \\(vol/vol) FCS.",
    "Transfer 10 ml suspensions in conical 15-ml tubes.",
    "15| Add 5 \u00b5L Hoechst<sub>33342</sub> stock solution \\(10 mg ml<sup>-1</sup>) per 10 ml cell suspension and incubate samples at 37 \u00b0C in the dark for 60 min; suspend cells at 15 min intervals.",
    "Chill samples on ice, spin down cells for 7 min at 400g at +4 \u00b0C and then wash the pellet once in 12 ml PBS containing 4% \\(vol/vol) FCS.",
    "Discard the supernatant and leave 50 \u00b5l staining medium over the cells.",
    "16| Remix cells in 200 \u00b5l medium and add 5 \u00b5l biotin-conjugated lineage marker antibodies.",
    "\\(Supplementary Table 2|).",
    "Incubate cells on ice for 30 min then wash twice with 10 ml medium. ",
    "17| Stir up 10<sup>7</sup> cells in 90 \u00b5l PBS containing 5% \\(vol/vol) normal rat serum and 0.05% \\(wt/vol) NaN<sub>3</sub> then add streptavidin-APC-Cy7 \\(1/100), anti-Sca-1 \\(FITC, 1/200), anti-c-kit \\(PE, 1/100) and anti-CD150 \\(APC, 1/50) antibody stock reagents on ice. ",
    "18| Incubate cells on ice for 60 min and add 10 \u00b5l 7-AAD stock solution during the last 10 min of labelling.",
    "Dilute samples with 4 ml ice cold IMDM containing 4% \\(vol/vol) FCS medium then filter the suspensions through 40-\u00b5m nylon meshes in 4-ml polystyrene FACS tubes.",
    "Spin down cells, discard supernatant and suspend cells in 1 ml IMDM complemented with 4% \\(vol/vol) FCS on ice for immediate FACS analysis and sorting. ",
    " ",
    "19| Analyse and sort cells by FACSvantage.",
    "Use standard settings \\(Supplementary Table 3|) and compensations for each fluorochrome calibrated on respective isotype controls. ",
    "20| At this point  putative HSCs in discrete BM fractions can be compared quantitatively either in the whole populations or in FACS enriched single cell fractions using in vitro cell-cycle analysis and proliferation kinetics, in vivo spleen colony forming unit \\(CFUs) frequencies and/or competitive marrow repopulating ability \\(CMRA) frequencies. ",
    "\\(A) Cell-cycle analysis<sup>54</sup>",
    "\\(i) Sort presumptive HSCs \\(Sp-KSL) \\(\u2265 10<sup>3</sup> cells per fraction) in ice-cold PBS complemented with 4% \\(vol/vol) FCS, and keep cells at 4 \u00b0C for 15-45 min. ",
    "\u25b2CRITICAL STEP",
    "This helps to minimize cell shape deformations.",
    "\\(ii)",
    "Spin down the cells \\(400g, 7 min) then suspend the pellet in 5 ml cold 4% \\(wt/vol) PFA for 10 min.",
    "\\(iii) Spin down fixed cells then suspend the pellet gently in 200 \u00b5l staining buffer \\(PBS) containing 10 \u00b5g ml-1 Hoechst33342 and 1.0 \u00b5g ml-1 Pyronin-Y. Stain cells for 1 h at RT then wash in 5 ml PBS.",
    "\\(iv)",
    "Analyse PY and Hoechst blue fluorescence by FACS<sup>54</sup> as indicated in Supplementary Table 3|.     ",
    " ",
    "**Clonal assays**",
    "\\(B)",
    "Single-cell in vitro growth kinetics ",
    "\\(i) Sort presumptive HSCs \\(e.g.",
    "Sp-KSL) individually into round-bottomed 96-well plates, previously filled with 150 \u00b5l My-LTCM supplemented with early acting growth factors \\(40 ng mSCF, 10 ng mVEGF, 10 ng mFlt3-L, 5 ng hTPO and 5 ng hIL-11).",
    "Incubate cells at 37 \u00b0C in humidified air with 5% CO<sub>2</sub>.",
    "\\(ii)",
    "Count cells in wells initially at 12-24 h intervals under an inverted microscope.",
    "Cell number can be estimated between about 300 and 30.000 cells per well taking advantage of the round-shape of colonies and arrangement of cells in a single layer.",
    "Enumerate cells forming the \u201cradius\u201d of the colony \\(see Fig.",
    "4Bc), then calculate surface value representing the total cell number per colony \\(n=r<sup>2</sup>\u03c0).",
    "Cell numbers over 30.000 cells per colony \\(i.e.",
    "when r\u2265100) are counted from small \\(i.e.",
    "15 \u00b5l) aliquots following suspension.",
    "\\(iii)",
    "At day 14 split individual cultures in aliquots by transferring 1/3 of the suspensions in new wells containing 100 \u00b5l cytokine supplemented fresh medium.",
    "Continue cell production in each well until the acrophase and decline of the actuary growth curve.",
    "Analyse clones according to length of cell-cycle quiescence, expansion potentials, total cell number and phenotype \\(Giemsa stained spin preparation; FACS)<sup>52, 55, 56</sup>. ",
    "\\(C) Spleen colony forming unit \\(CFU-S)<sup>36</sup> using Rosa26 donor cells and competitive marrow repopulating ability \\(CMRA) assays",
    " \\(i) Irradiate wild type, male host mice \\(C57/B6-CD45.2 phenotype; 2-4 month old, 6 per group) at 9.5 Gy on day -1 of graft injection.",
    "\\(ii)",
    "Sort increasing number of presumptive HSCs, \\(i.e.",
    "10, 30 or 90 Lin<sup>neg</sup>SpSK cells) in individual wells containing 100 \u00b5l IMDM containing 0.5% \\(vol/vol) BSA, either from ROSA-26 BM for CFUs and CRU assays, or from C57/B6-CD45.1 mice for CRU only assay. ",
    "\\(iii) Add to the sorted donor cells 10<sup>5</sup> normal competitor C57/B6-CD45.2 BM cells in 100 \u00b5l IMDM containing 0.5% \\(wt/vol)",
    "BSA  per well then inject the totality of cells in 200 \u00b5l i.v. using 30G \\(0.3x8 mm) insulin syringes via the retro-orbital plexus.",
    "\\(iv)",
    "Spleen colony-forming unit \\(CFU-S<sub>d12</sub>) assay, splenectomy and identification of ROSA-26 donor-derived colonies ",
    "\\(Box3|)  ",
    "\\(v) CMRA assay <sup>57, 58, 59</sup>",
    "Analyse blood cell chimeras in transplanted mice at \u22654 months.",
    "Take 50 \u00b5l peripheral blood from the retro-orbital plexus into heparinised syringes, dilute in 1 ml PBS containing 20 IU heparin and keep on ice until processing.",
    "Centrifuge at 400g for 5 min then carefully remove the supernatant.",
    "Remix pellet for 5 sec then add 1.6 ml RBC lysis buffer for 2 min at RT; stop osmotic lyses immediately when red colour turns deeper by adding 200 \u00b5l FCS and centrifuge cells at 4 \u00b0C.",
    "Remix the pellet in ice-cold 1 ml PBS containing 4% \\(vol/vol) FCS. ",
    "Analyse donor derived cells by FACS, using rat anti-mouse CD45.1, FITC conjugated antibody or by the fluorescent substrate FDG \\(FITC channel) when ROSA26 donor cells were used.",
    "Quantify B-cells by B220 \\(APC) and myeloid cells by CD11\\(Gr)\\(PE) RaM antibodies.  ",
    "\\(vi) Detect intracellular FDG positive cells according to the protocol provided by the furnisher \\(Molecular Probes/Invitrogen) ",
    "\\(vii) Apply standard statistical methods for calculation cell frequency or CMRA<sup>57, 58</sup>",
    "**Topographical mapping of haematon units** ",
    "21| Apply coloured hydrogel angiography to reveal tissue units in solid organs and to investigate analogous haematon units in relation with the vascular system along the femur \\(Fig.",
    "3|)<sup>SAR-6,-8,-9,-10</sup>.",
    "Bisect femur following hydrogel casting and Zn-7 fixation, wash in pH 6.2 buffer and remove loosely attached cells by gentle agitation through a 200-\u00b5l pipette in a Petri dish. ",
    "\u25b2CRITICAL STEP Careful dilaceration of the BM shaft facilitates diffusion of reagents.  ",
    "\\(i)",
    "Replace buffer by acetyl-cholinesterase reaction solution for 3-4 h at RT in the dark \\(Supplementary Method 4).",
    "Wash the preparation in Tris buffer, fix again in Zn-7 at RT for 30 min, dehydrate in 30, 50 and 70% \\(vol/vol) ethanol for 30 min then rehydrate in 100 mM Tris at pH8.1. ",
    "\\(ii)",
    "Aspirate washing buffer and add 5 ml alkaline phosphatase reaction solution",
    "\\(Supplementary Method 6) until background colouration starts to appear \\(usually 30-40 min).",
    " ",
    "\\(iii) Stain bone with Alizarin red and cartilage with Alcian blue overnight at 37 \u00b0C.",
    "Clear background colouration by repeated changes in 1% \\(wt/vol)",
    "KOH/20% \\(vol/vol) glycerin bath. ",
    "\\(Supplementary Method 2)",
    "\\(iv)",
    "Clear in 1% KOH as above then analyse and photograph the tissue under dark-field stereomicroscopy.        ",
    "**Laser confocal-scanning microscopy \\(LCSM)**",
    "22| Fig.",
    "1| guides the preparation of native \\(A-D-I) haematon particles for 3D LCSM.",
    "23|",
    "Fix haematons in Zn-7 for 4-24 h at 4 \u00b0C; wash 3x1 h in 100 mM Tris-HCl buffer pH7.5",
    "\u25b2CRITICAL STEP Manipulate haematon isolates using silicon-coated pipette tips and centrifuge tubes. ",
    "24| Immobilize haematon particles in a fine sheet of alginate hydrogel. ",
    "\\(Box 3|)",
    "\u25b2CRITICAL STEP This step is indispensable for multicolour labelling to protect from disintegration and for investigation of haematon particles containing abundant lipocytes/adipocytes that make them sticky and floating \\(for example human BM haematons)",
    "25| Proceed with haematon staining for identifying HSCs and niche-forming cells either by external membrane-localized markers, ECM components or by intracellular markers. ",
    " ",
    "Labeling for putative HSCs, extracellular matrix and morphogen molecules",
    "\\(i)",
    "Saturate non-specific binding sites in 100 mM Tris-HCl buffer \\(pH7.5), 0.9% \\(wt/vol)",
    "NaCl containing 2% \\(vol/vol) normal rat serum \\(TNRS) for 2 h. ",
    "\\(ii)",
    "Add to the alginate embedded haematon preparation in 200 \u00b5l TNRS biotinylated rat anti-Tie2 MoAb \\(1:50 dilution) for 2 h.",
    "\\(iii) Wash 3x20 min in 2 ml buffer at 4 \u00b0C.",
    "Add in 200 \u00b5l TNRS buffer 1:100 diluted streptavidin-APC/Cy7 and directly conjugated fluorochrome-labelled primary rat Abs to Sca-1 \\(1:100, FITC), c-kit \\(1:100, PE) and CD150 \\(1:50, APC).",
    "\\(iv)",
    "Add DAPI 1.0 \u00b5g ml-1 at the last step for 30 min. \\(optional)",
    "\\(v)",
    "Wash the sheet of haematons \\(2x1 h) in TNRS then remove buffer completely using a 30G needle.",
    "\\(vi)",
    "Add 50 \u00b5l Mowiol prior to transfer and mounting on microscope slide.",
    "Labeling niche-forming cells and intracellular components ",
    "\\(i)  ",
    "Following Zn-7 fixation and wash dehydrate haematons through 30-50 and 70% ",
    "\\(vol/vol) ethanol in d.w. \\(15-15-60 min, respectively) ",
    "\u25a0 PAUSE POINT Samples can be stored overnight in 70% \\(vol/vol) ethanol at 4 \u00b0C. ",
    "\\(ii)",
    "Rehydrate first in Tris-HCl then incubate in 100 mM Tris-1% \\(wt/vol) albumin-0.1% \\(vol/vol)",
    "Triton X-100 pH7.5 \\(TAT washing buffer) containing 5% \\(vol/vol) normal blocking serum. ",
    "\u25b2CRITICAL STEP Aliquot identical cohorts of haematon particles for parallel labelling purposes",
    "\\(iii) Add to pellet primary antibody \\(1/20 to 1/100 dilution;  1 \u00b5g Ab per 10<sup>6</sup> cells) in TAT for 6-16 h.",
    "\\(iv)",
    "Wash pellet 3-times in TAT containing 2% \\(vol/vol) normal serum for 30 min.",
    "\\(v)",
    "Add biotin conjugated secondary antibody at 1/100 dilution for 4-6 h \\(or alternative reagent), wash in TAT twice then add TAT containing 5% \\(vol/vol) NRS for 60 min. ",
    "\\(vi) Add to 2 \u00b5l streptavidin-PE \\(or 2 \u00b5l streptavidin-Alexa-546) and fluorochrome conjugated primary antibodies \\(2 \u00b5l Sca1-FITC, 4 \u00b5l CD150-APC) in 200 \u00b5l TAT containing 5% \\(vol/vol) normal rat serum for 6-16 h.  ",
    "\\(vii) Add DAPI 1.0 \u00b5g ml-1 at the last step for 30 min. \\(optional)",
    "\\(viii)",
    "Wash 3x1 h in TAT at 4 \u00b0C. ",
    "26| Proceed montage for LSCM analysis.",
    "Transfer haematons in 40 \u00b5l Mowiol on clean Superfrost slide, remove occasional thick clumps under the stereomicroscope, place the coverslip \\(15x15 mm) and then stick the coverslip with nail polish to hinder evaporation. ",
    "\u25a0 PAUSE POINT",
    "The preparations can be stored for several weeks at +4 \u00b0C in the dark. ",
    "27| Acquire image series under the LSCM and produce 3D animation ",
    "\\(EQUIPMENT SETUP)",
    "In our settings confocal images are presented as Z-stack projections; 30\u201390 optical sections in 0.2\u20132.0 \u00b5m increments.",
    "3D reconstructed projections shown in Fig.3Bc-f and in the supplementary Movie 2| was generated using LSM510 software v3.0 \\(Carl Zeiss MicroImaging, Inc.)",
    "For figure preparation, Adobe Photoshop vCS3 was used for adjustments of brightness and for colour balance.",
    "LCSM 3D animation ",
    "Supplementary Video 2| ",
    "**Transmission electron microscopy** \\(TEM)",
    "28|",
    "Sample preparation and analysis",
    "\\(i)",
    "Fix haematon isolates in 2% \\(wt/vol) paraformaldehyde or 4% \\(wt/vol) glutaraldehyde in 0.1 M Na-cacodylate buffer \\(pH 7.2) for 2-4 h at +4\u00b0C.",
    "\\(ii)",
    "Wash the haematon pellet three times 1 h in Ca-free buffer at +4\u00b0C.",
    "\\(iii)Protect haematons from disintegration by admixing 1% \\(wt/vol) alginate pre-polymer in 0.9% NaCl \\(wt/vol), collection on a 30 \u00b5m mesh filter, followed by polymerization of the filter retained haematons in a thin layer of alginate using 0.9% NaCl bath containing 10 mM CaCl<sub>2</sub>.",
    "Identify representative haematons and cut with the alginate layer under a stereomicroscope for processing.   ",
    "\u25cfTIMING  One to 2 d.",
    "\\(iv)",
    "Dehydrate in graded series of ethanol and propylene dioxide.",
    "\\(v) Proceed inclusion according to standard technique provided by the manufacturer.",
    "\u25cfTIMING  Three to 4 d.",
    "\\(vi) Cut semi-thin \\(0.5-1 \u00b5m thin) or ultrathin \\(gold to silver colour) sections with a Reichert-UM2 microtome and collect sections either on a clean microscope slide or formvar-coated micro-grid, respectively.",
    "\\(vii) Stain semi-thin sections in hematoxilin/fast green or in 2% toluidine blue solution containing 60% sucrose at 90\u00b0C for 2 min. and stain thin sections by uranyl acetate and lead citrate in sequence.",
    "\u25cfTIMING  Two to 3 d.",
    "\\(viii)",
    "We studied samples under a JEOL 100C EM at 100-kV accelerating voltage.",
    "**Micro-Computer Tomography \\(micro-CT)**",
    "29| Sample preparation ",
    "\\(i) Dissect the bone sample and remove the surrounding soft tissues.",
    "\\(ii)",
    "Dehydrate the bone in 30-50-70% \\(vol/vol) ethanol \\(1 h each) and then rehydrate in d.w.",
    "in order to minimize bone deformation during measurement.",
    "\\(iii) Insert firmly a tiny, short pin at one side of the bone and seal this end on the central holder using light-curing bonding resin \\(Heliobond, Vivadent).    ",
    "30| Scanning ",
    "Immobilized bone samples were scanned at 360\u00b0 rotation at 0.7 degree intervals.",
    "\u25cfTIMING  Six to 24 h, depending on the size of sample.",
    "31| Calculations ",
    "For reconstruction of 2D and 3D images we used the cone beam volumetric algorithm \\(Feldkamp).",
    "Measurements were made on the Region of Interest \\(ROI) \u00d7",
    "1.5 mm Tissue Volume \\(TV) on the computer-reconstructed 3D samples.",
    "For selected skeleton segments seven parameters are calculated: 1) total bone volume, 2) total \u201cempty\u201d volume, corresponding to the BM parenchyma, 3) surface of intersection, which corresponds to the endosteal and spongy bone surface, 4) trabecular separation \\(plate model), 5) trabecular diameter \\(rod model), 6) trabecular separation, and 7) trabecular number<sup>53</sup> ."
]